All patients
non invasive oxygen
anti-inflammatory therapies in COVID-19 (hospitalized or not) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Abu Esba LC (any NSAID use, acute and chronic), 2020 0.49 [0.18; 1.36]
Lund, 2020 1.02 [0.57; 1.82]
Manenti, 2021 0.24 [0.09; 0.65]
Rinott, 2020 1.22 [0.32; 4.60]
Wong (OpenSAFELY) (Study 1: General population, any NSAID), 2020 0.95 [0.80; 1.13]
0.75 [0.48 ; 1.18 ] Abu Esba LC (any NSAID use, acute and chronic), 2020, Lund, 2020, Manenti, 2021, Rinott, 2020, Wong (OpenSAFELY) (Study 1: General population, any NSAID), 2020 5 54% 2,097 NA not evaluable deaths (time to event analysis only)detailed results Manenti, 2021 0.24 [0.09; 0.65]
0.24 [0.09 ; 0.65 ] Manenti, 2021 1 0% 71 NA not evaluable hospitalizationdetailed results Abu Esba LC (any NSAID use, acute and chronic), 2020 1.54 [1.06; 2.24]
Gianfransesco, 2020 0.64 [0.39; 1.06]
Lund, 2020 1.16 [0.87; 1.54]
1.08 [0.71 ; 1.65 ] Abu Esba LC (any NSAID use, acute and chronic), 2020, Gianfransesco, 2020, Lund, 2020 3 74% 2,064 NA not evaluable mechanical ventilationdetailed results Abu Esba LC (any NSAID use, acute and chronic), 2020 0.92 [0.48; 1.75]
Lund, 2020 1.14 [0.56; 2.31]
Rinott, 2020 0.93 [0.43; 2.01]
0.99 [0.66 ; 1.48 ] Abu Esba LC (any NSAID use, acute and chronic), 2020, Lund, 2020, Rinott, 2020 3 0% 2,021 NA not evaluable ICU admissiondetailed results Lund, 2020 1.04 [0.54; 2.01]
Rinott, 2020 1.42 [0.49; 4.10]
1.13 [0.65 ; 1.99 ] Lund, 2020, Rinott, 2020 2 0% 1,515 NA not evaluable severe COVID-19 occurrencedetailed results Abu Esba LC (any NSAID use, acute and chronic), 2020 0.73 [0.34; 1.56]
0.73 [0.34 ; 1.56 ] Abu Esba LC (any NSAID use, acute and chronic), 2020 1 0% 503 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-23 16:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 87
- treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615
- roots T: 290
